Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management

July 2002 in “ The Neurologist ”

Elliot M. Frohman, Ted Phillips, Kristen Kokel, Jerry Van Pelt, Shirley O’Leary, Shelly Gross, Kathleen Hawker, Michael K. Racke

interferon beta-1a interferon beta-1b glatiramer acetate skin reactions flu-like symptoms spasticity bladder dysfunction fatigue heat sensitivity headaches mood disorders menstrual abnormalities pregnancy considerations autoimmune disorders capillary leak syndrome IFN beta-1a IFN beta-1b Copaxone

Studysummary This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on journals.lww.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Multiple Sclerosis: Side Effects of Interferon Beta Therapy and Their Management

284 citations , November 1999 in “Neurology”

This article discusses the side effects of interferon beta therapy for MS, including flu-like symptoms and autoimmune reactions, and provides guidance on their management but does not report new clinical findings.